Cancer Immunotherapy Market Report

Cancer Immunotherapy Market Analysis By Product (Monoclonal Antibodies, Immunomodulators, Oncolytic Viral Therapies, Cancer Vaccines), By Cancer Type, And Segment Forecasts, 2018 - 2025

  • Published Date: Oct, 2017
  • Base Year for Estimate: 2016
  • Report ID: GVR-1-68038-693-6
  • Format: Electronic (PDF)
  • Historical Data: 2014 - 2015
  • Number of Pages: 75

Industry Insights

The global cancer immunotherapy market size was valued at USD 40.7 billion in 2016. Growing adoption of advanced therapeutics coupled with rising incidence of cancer are key factors propelling the overall market. Healthcare providers are focusing on improving treatments and reduction in recurrence of cancer post chemotherapy. However, high prices of drugs and adverse effects associated with them are affecting market growth. 

Rising R&D in cancer immunotherapy is resulting in introduction of advanced treatment options that are more effective and efficient. A paradigm shift from traditional chemotherapies to immunotherapies is propelling the overall market.

China cancer immunotherapy market

Frequent introduction of new drugs has resulted in increase in competitive rivalry. Immunomodulatory drugs, such as thalidomide, lenalidomide, and pomalidomide, were the best treatment options available in the past few years. Introduction of newer drug classes, such as monoclonal antibodies and HDAC inhibitors, designed to target receptors related to multiple myeloma, is expected to initiate newer trends in the market. Ongoing studies on similar drugs designed to minimize side effects are expected to propel the market for these drug classes in the multiple myeloma therapeutics market.

In addition, approval of PD-1 and CTLA-4 checkpoint inhibitors for melanoma and Non-Small Cell Lung Cancer (NSCLC) is boosting the market. Approval of innovative immunotherapy drug forms, such as vaccines and adjuvants, is on the rise. Moreover, more immunotherapies are being tested for enhanced outputs, such as immunomodulators and CAR T-cell therapy. These new approvals and ongoing research in chemoimmunotherapy is driving the global market.

On the other hand, currently available therapies have severe adverse effects, such as pain, insomnia, fatigue, nausea, gastrointestinal conditions, and non-targeted actions, which affect the quality of life of patients. In addition, management of these adverse effects incurs extra cost. Also, prolonged consumption of immunotherapeutic drugs is likely to cause destruction of major organs and organ failure. Other side effects include skin reactions, mouth sores, and flu-like symptoms. These factors are restraining market growth. The number and intensity of adverse effects challenge the entry of newer drugs in the market.

Product Insights

Monoclonal antibodies was the largest segment in 2016. Increasing investments on R&D of monoclonal antibodies as naked antigen binding antibodies, conjugated monoclonal antibodies, and bispecific antibodies have opened new avenues of revenue generation for companies that provide oncology therapeutics. These R&D activities are resulting in introduction of Monoclonal Antibodies (mAbs) that have effects, such as adaptive immunity, antigen specificity, and antibody dependent cellular toxicity. Owing to several benefits of mAbs, they are being studied for treatment of various types of tumors.

Immunomodulators, unlike other chemo-immunotherapy drugs, are used to modulate the immune system of patients, which, in turn, enhances the activity of the immune system against cancer. Immunomodulators, such as cytokine modulators and growth factors, are nonspecific therapies. These nonspecific therapies are designed to act as immune stimulating agents leading to better immune responses against tumor cells. 

Rising effectivity and accuracy of these immunomodulatory drugs has resulted in increasing their market penetration. Along with these approved drugs, market players are working toward introducing several novel therapies.

Cancer Type Insights

Majority of immunotherapy drugs approved are for NSCLC, including few monoclonal antibodies and checkpoint inhibitors. Monoclonal antibodies successfully prevent formation of new blood vessels by tumor cells, thus facilitating inhibition of an alternative path for growth of tumor cells. Checkpoint inhibitors are used as a first-line treatment in patients suffering from advanced lung tumor. Opdivo, Keytruda, and Tecentriq are immunotherapeutic drugs approved for lung tumor. These drugs are usually prescribed in cases of reoccurrence of tumor post chemotherapy. The aforementioned factors are anticipated to boost adoption of these drugs. On the other hand, life-threatening side effects of these drugs, such as organ damage, are expected to restrain the market. 

Breast cancer, if diagnosed early, is usually treated by surgery first followed by other chemotherapeutic treatments. In addition, breast cancer has been observed to be immunologically silent. R&D efforts and preclinical studies have been conducted to prove the efficacy of immunotherapeutic drugs for breast cancer treatment.

Immunotherapy holds a large share in the melanoma therapeutics segment owing to development of new products, large number of FDA approvals, and extensive R&D in this field. The U.S. FDA has recently approved three checkpoint inhibitors for melanoma treatment, three cytokine therapies, and one oncolytic virus therapy. Keytruda, Yervoy, and Opdivo are commercially available checkpoint inhibitors which boost the patient’s immune response against melanoma cells, thus shrinking tumors and increasing the lifespan of patients suffering from advanced melanoma.

Global cancer immunotherapy market

Regional Insights

North America held the largest revenue share in 2016. Rising incidence of the disease, increasing ease of access to modern therapeutics, coupled with expanding geriatric population, is propelling the market in the region. On the other hand, factors, such as challenges in clinical trials, coupled with higher costs and rapidly changing reimbursement policies, are impeding growth of the market in North America. 

Asia Pacific is expected to experience fastest growth. Rising incidence of the disease and in turn, rising mortality rate is propelling demand for immunotherapy in the region. Moreover, presence of market players with major investments in the market, such as AstraZeneca; Merck & Co., Inc.; and Pfizer, Inc., is boosting the Asia Pacific market.

New and advanced immunotherapy drugs are being introduced in China and Japan. These countries have several ongoing clinical trials as well as FDA approvals for new drug molecules and combination therapies. Approval of new treatment drugs in China and Japan are boosting adoption of immunotherapy for treatment of tumors.

Competitive Insights

The global market is highly competitive. Key players include Amgen, Inc.; AstraZeneca; F. Hoffmann La Roche Ltd.; Bayer AG; Bristol-Myers Squibb Company; Eli Lilly and Company; Merck and Co., Inc.; Novartis AG; and Pfizer, Inc. 

Key parameters affecting competition are rapid adoption of advanced treatment options for improved healthcare coupled with the rising need for optimum capital utilization. In addition, major players are frequently engaging in mergers & acquisitions to retain their market share and diversify their product portfolio.

Report Scope



Base year for estimation


Actual estimates/Historical data

2014 - 2015

Forecast period

2017 - 2025

Market representation                                                

Revenue in USD Billion and CAGR from 2017 to 2025

Regional scope

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Country scope

U.S., Canada, U.K, Germany, China, India, Mexico, Brazil, South Africa

Report coverage             

Revenue forecast, company share, competitive landscape, growth factors, and trends

15% free customization scope (equivalent to 5 analyst working days)

If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization

Segments covered in the report

This report forecasts revenue growth at global, regional & country levels and provides an analysis on the industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global cancer immunotherapy market based on product, cancer type and region:

  • Product Outlook (Revenue, USD Billion, 2014 - 2025)

    • Monoclonal Antibodies

    • Immunomodulators

    • Oncolytic Viral Therapies and Cancer Vaccines

  • Cancer Type Outlook (Revenue, USD Billion, 2014 - 2025)

    • Lung Cancer

    • Breast Cancer

    • Colorectal Cancer

    • Melanoma

    • Prostate Cancer

    • Head and Neck Cancer

    • Ovarian Cancer

    • Pancreatic Cancer

  • Regional Outlook (Revenue, USD Billion, 2014 - 2025)

    • North America

      • U.S.

      • Canada

    • Europe

      • U.K.

      • Germany

    • Asia Pacific

      • India

      • China

    • Latin America

      • Brazil

      • Mexico

    • Middle East & Africa

      • South Africa

Key questions answered by the report
Request for Customization

Choose License Type

Single User - $4,950
Multi User (2-5) - $5,950
Enterprise Access - $7,950

Buy Chapters or Sections

Avail customized purchase options to meet your exact research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Why Choose Us

  • Research support

    24/5 Research support

    Get your queries resolved from an industry expert.

  • Custom research service

    Custom research service

    Design an exclusive study to serve your research needs.

  • Quality assurance

    Quality assurance

    A testimonial for service in the form of BBB "A" Accreditation.

  • BBB Rating dandb
  • Information security

    Information security

    Your personal and confidential information is safe and secure.

  • grand view research PCI DSS complaint grand view research paypal verified